Abstract:Gene therapy has emerged as a promising approach for treating a wide range of genetic and acquired diseases by introducing or modifying genetic material within cells. To achieve successful gene therapy, efficient and precise delivery of genetic material, such as DNA or RNA, to target cells is essential. This abstract explores the development of both non-viral and viral vectors for the delivery of genetic material in gene therapy applications. Non-viral vectors, including lipid nanoparticles (LNPs), polymer-based carriers, and cell-penetrating peptides, have gained significant attention due to their safety profile and ease of production. These vectors are designed to protect genetic material from degradation, facilitate cellular uptake, and release the cargo at the desired location. Recent advancements in nanotechnology have enabled the design of customizable non-viral vectors with enhanced delivery efficiency and reduced offtarget effects. Viral vectors, on the other hand, harness the natural infectivity of viruses to transport genetic material into target cells. Retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAVs) are commonly used viral vectors in gene therapy. Viral vectors offer high transduction efficiency but may trigger immune responses or pose risks of insertional mutagenesis. Efforts in vector engineering have led to the development of safer viral vectors with improved targeting capabilities and reduced immunogenicity. AAVs, in particular, have gained prominence due to their ability to achieve long-lasting gene expression with minimal adverse effects. Targeted delivery strategies aim to enhance vector specificity, ensuring that genetic material reaches the intended cell type or tissue. These strategies include modifying vector surface proteins, employing tissue-specific promoters, or utilizing ligand-receptor interactions. In conclusion, the successful application of gene therapy relies on the development of efficient and targeted delivery systems for genetic material. Non-viral and viral vectors offer distinct advantages and continue to evolve to meet the demands of gene therapy applications. Advances in vector design, safety, and targeting strategies hold promise for the continued progress of gene therapy as a transformative medical intervention.

Chemical Modification Strategies of Viral Vectors for Gene Therapy

Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects

Non-viral vectors for gene-based therapy

Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression

Chemical Modification of Chitosan As a Gene Transporter

Gene Therapy Progress and Prospects: Nonviral vectors

Developing non-viral or viral vectors for efficient and targeted delivery of genetic material, such as DNA or RNA, for gene therapy applications

What Can We Learn from Virus in Designing Nonviral Gene Vectors

Viral vector‐based gene therapies in the clinic

Viral vector platforms within the gene therapy landscape

Current status of gene therapy vector research

[Nanobiotechnological Gene Transfer Vectors in Gene Therapy].

The evolution of adenoviral vectors through genetic and chemical surface modifications

Application of Non-Viral Vectors in Drug Delivery and Gene Therapy

Chemical modification of chitosan for efficient gene therapy.

Nanobiomaterial Vectors for Improving Gene Editing and Gene Therapy

The Development of Functional Non-Viral Vectors for Gene Delivery

Clinical and Translational Landscape of Viral Gene Therapies

A primer to gene therapy: Progress, prospects, and problems

AAV-Based Targeting Gene Therapy

Polymers as Efficient Non-Viral Gene Delivery Vectors: The Role of the Chemical and Physical Architecture of Macromolecules